Important Announcements

Nondiscrimination Statement Update

Boston Medical Center Health System complies with applicable Federal civil rights laws and does not discriminate on the basis of age, race, color, national origin (including limited English proficiency and primary language), religion, culture, physical or mental disabilities, socioeconomic status, sex, sexual orientation and gender identity and/or expression. BMCHS provides free aids and services to people with disabilities and free language services to people whose primary language is not English.

To see our full nondiscrimination statement, click here.

Campus Construction Update

Starting September 14, we’re closing the Menino building lobby entrance. This, along with the ongoing Yawkey building entrance closure, will help us bring you an even better campus experience that matches the exceptional care you've come to expect. Please enter the Menino and Yawkey buildings through the Moakley building, and make sure to leave extra time to get to your appointment. Thank you for your patience. 

Click here to learn more about our campus redesign. 

PROFESS

Select your language:

PROFESS: Prevention Regimen For Effectively avoiding Second Strokes

Sponsor: Boehringer Ingelheim

Investigators: Carlos Kase MD, Viken Babikian MD, Jose Romero MD

PRoFESS Results Announced At XVII European Stroke Conference on Thursday 15 May 2008.

The PRoFESS trial, a large clinical research study for secondary stroke prevention showed that the recurrent stroke event rates for Aggrenox and clopidogrel were similar. In further exploratory analysis of the main secondary endpoint of the composite of stroke, myocardial infarction or vascular death, AGGRENOX and clopidogrel showed similar outcomes (13.1% versus 13.1%). In PRoFESS, the AGGRENOX arm had a higher number of hemorrhagic strokes compared to clopidogrel (0.8% and 0.4%, respectively) while ischemic stroke recurrences were less frequent in the AGGRENOX arm compared to the clopidogrel arm (7.7% and 7.9%, respectively). A post-hoc analysis showed comparable numbers of death and disabling strokes and a similar neurological outcome as measured by the modified Rankin Scale at three months after the recurrent stroke and at the end of the PRoFESS trial between the two treatment arms.